These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27107744)

  • 1. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms.
    Gugliotta L; Iurlo A; Gugliotta G; Tieghi A; Specchia G; Gaidano G; Scalzulli PR; Rumi E; Dragani A; Martinelli V; Santoro C; Randi ML; Tagariello G; Candoni A; Cattaneo D; Ricco A; Palmieri R; Liberati MA; Langella M; Rago A; Bergamaschi M; Monari P; Miglio R; Santoro U; Cacciola R; Rupoli S; Mastrullo L; Musto P; Mazzucconi MG; Vignetti M; Cortelezzi A; Vianelli N; Martino B; De Stefano V; Passamonti F; Vannucchi AM;
    Leuk Res; 2016 Jul; 46():18-25. PubMed ID: 27107744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic and bleeding complications in classical myeloproliferative neoplasms.
    McMahon B; Stein BL
    Semin Thromb Hemost; 2013 Feb; 39(1):101-11. PubMed ID: 23264112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide.
    Schwarz J; Ovesná P; Černá O; Kissová J; Maaloufová Soukupová J; Brychtová Y; Doubek M; Červinek L; Cmunt E; Dulíček P; Campr V; Křen L; Penka M;
    Eur J Haematol; 2016 Jan; 96(1):98-106. PubMed ID: 25807961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
    Martinelli I; De Stefano V; Carobbio A; Randi ML; Santarossa C; Rambaldi A; Finazzi MC; Cervantes F; Arellano-Rodrigo E; Rupoli S; Canafoglia L; Tieghi A; Facchini L; Betti S; Vannucchi AM; Pieri L; Cacciola R; Cacciola E; Cortelezzi A; Iurlo A; Pogliani EM; Elli EM; Spadea A; Barbui T
    Am J Hematol; 2014 Nov; 89(11):E200-5. PubMed ID: 25042466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Andıç N; Ünübol M; Yağcı E; Akay OM; Yavaşoğlu İ; Kadıköylü VG; Bolaman AZ
    Turk J Haematol; 2016 Sep; 33(3):187-95. PubMed ID: 27094255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms.
    Mihaila RG
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Mar; 161(1):50-53. PubMed ID: 28145534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.
    Carobbio A; Finazzi G; Antonioli E; Guglielmelli P; Vannucchi AM; Delaini F; Guerini V; Ruggeri M; Rodeghiero F; Rambaldi A; Barbui T
    Blood; 2008 Oct; 112(8):3135-7. PubMed ID: 18587010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
    Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the thrombotic risk in patients with myeloproliferative neoplasms.
    Vianello F; Battisti A; Cella G; Marchetti M; Falanga A
    ScientificWorldJournal; 2011 May; 11():1131-7. PubMed ID: 21623459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients.
    Edahiro Y; Kurokawa Y; Morishita S; Yamamoto T; Araki M; Komatsu N
    Intern Med; 2022; 61(22):3323-3328. PubMed ID: 36385045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms.
    Seguro FS; Teixeira LLC; da Rosa LI; da Silva WF; Nardinelli L; Bendit I; Rocha V
    J Thromb Thrombolysis; 2020 May; 49(4):667-672. PubMed ID: 31898273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thrombohaemorrhagic syndrome in patients with a myeloproliferative disease with thrombocythemia].
    Penka M; Kissová J; Buliková A; Zavrelová J; Ovesná J; Pavlík T
    Vnitr Lek; 2011 Mar; 57(3):306-11. PubMed ID: 21495413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
    Kander EM; Raza S; Zhou Z; Gao J; Zakarija A; McMahon BJ; Stein BL
    Int J Hematol; 2015 Nov; 102(5):587-93. PubMed ID: 26440973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group.
    Gutwein O; Lavi N; Barzilai M; Shacham-Abulafia A; Leader A; Chubar E; Dally N; Shapira S; Mishchenko E; Ellis M; Koren-Michowitz M
    Acta Haematol; 2021; 144(4):438-445. PubMed ID: 33316809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.
    Marchetti M; Falanga A
    Pathophysiol Haemost Thromb; 2008; 36(3-4):148-59. PubMed ID: 19176988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.
    Ar MC; Hatemi G; Ekizoğlu S; Bilgen H; Saçli S; Buyru AN; Soysal T; Ülkü B; Yazici H
    Clin Appl Thromb Hemost; 2012 Jul; 18(4):421-6. PubMed ID: 22203033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.